Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 2Waldenstrom Macroglobulinemia 1Precancerous Conditions 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 27Rituximab 20Etoposide 14Cytarabine 13Melphalan 11Vincristine 10fludarabine 9Prednisone 9Doxorubicin 9Busulfan 8Peripheral Blood Stem Cell Transplantation 7Radiotherapy 6Filgrastim 6Cyclosporine 6Bendamustine Hydrochloride 6fludarabine phosphate 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5Mycophenolic Acid 5Cisplatin 5tositumomab I-131 4ibritumomab tiuxetan 4Ifosfamide 4Dexamethasone 4Carmustine 4relmacabtagene autoleucel 3Thiotepa 3Indium 3Immunotherapy, Adoptive 3Gemcitabine 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Non-Hodgkin × alethine × Clear all
NCT00007839 2013-12-18

Beta Alethine in Treating Patients With Low-Grade Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡